Key points from article :
Biotech company BioAge raised $170 million to develop new obesity drugs.
Their lead drug, azelaprag, mimics an exercise hormone and is taken orally, unlike injections.
Azelaprag may boost weight loss and improve body composition when combined with existing drugs.
Early studies show azelaprag promotes muscle metabolism, increases energy expenditure, and prevents muscle loss.
Phase 2 trials combining azelaprag with Lilly's Zepbound are planned for mid-2024.
This funding will also support BioAge's research on other metabolic diseases.
